Dabigatran Etexilate Mesylate Patent Expiration

Dabigatran Etexilate Mesylate is used for preventing and treating blood clots. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc in its drug Pradaxa on Oct 19, 2010. 5 different companies have introduced drugs containing Dabigatran Etexilate Mesylate.


Dabigatran Etexilate Mesylate Patents

Given below is the list of patents protecting Dabigatran Etexilate Mesylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Pradaxa US6087380 Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions Feb 18, 2018

(Expired)

Boehringer Ingelheim
Pradaxa US6087380 Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions Dec 28, 2021

(Expired)

Boehringer Ingelheim
Pradaxa US6087380

(Pediatric)

Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions Jun 28, 2022

(Expired)

Boehringer Ingelheim
Pradaxa US7866474 Film container Aug 31, 2027 Boehringer Ingelheim
Pradaxa US7866474

(Pediatric)

Film container Mar 02, 2028 Boehringer Ingelheim
Pradaxa US7932273 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament Sep 07, 2025 Boehringer Ingelheim
Pradaxa US7932273

(Pediatric)

3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament Mar 07, 2026 Boehringer Ingelheim
Pradaxa US9034822 Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds Jan 20, 2031 Boehringer Ingelheim
Pradaxa US9034822

(Pediatric)

Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds Jul 20, 2031 Boehringer Ingelheim
Pradaxa US9925174 Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof Jun 14, 2023

(Expired)

Boehringer Ingelheim
Pradaxa US9925174

(Pediatric)

Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof Dec 14, 2023

(Expired)

Boehringer Ingelheim


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Dabigatran Etexilate Mesylate Generics

Several generic applications have been filed for Dabigatran Etexilate Mesylate. The first generic version for Dabigatran Etexilate Mesylate was by Alkem Laboratories Ltd and was approved on Mar 11, 2020. And the latest generic version is by Msn Laboratories Private Ltd and was approved on May 22, 2024.

Given below is the list of companies who have filed for Dabigatran Etexilate Mesylate generic.


1. ALKEM LABS LTD

Alkem Laboratories Ltd has filed for 2 different strengths of generic version for Dabigatran Etexilate Mesylate. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 75MG BASE capsule Prescription ORAL AB Mar 11, 2020
EQ 150MG BASE capsule Prescription ORAL AB Mar 11, 2020


2. MSN

Msn Laboratories Private Ltd has filed for 2 different strengths of generic version for Dabigatran Etexilate Mesylate. Given below are the details of the strengths of this generic introduced by Msn.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 75MG BASE capsule Prescription ORAL AB May 22, 2024
EQ 150MG BASE capsule Prescription ORAL AB May 22, 2024


3. APOTEX

Apotex Inc has filed for 3 different strengths of generic version for Dabigatran Etexilate Mesylate. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 110MG BASE capsule Prescription ORAL AB Dec 15, 2023
EQ 150MG BASE capsule Prescription ORAL AB Dec 15, 2023
EQ 75MG BASE capsule Prescription ORAL AB Dec 15, 2023


4. HETERO LABS LTD III

Hetero Labs Ltd Unit Iii has filed for 2 different strengths of generic version for Dabigatran Etexilate Mesylate. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 75MG BASE capsule Prescription ORAL AB May 6, 2020
EQ 150MG BASE capsule Prescription ORAL AB May 6, 2020